S8809-S9800-S9911-S9704-A Study of Blood and Tissue Samples From Patients With Follicular Lymphoma Treated With Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone
NCT00933127 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 142
Last updated 2014-07-24
Summary
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.
PURPOSE: This research study is looking at blood and tissue samples from patients with follicular lymphoma treated with rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone.
Conditions
Interventions
- GENETIC
-
DNA analysis
- GENETIC
-
polymerase chain reaction
- GENETIC
-
polymorphism analysis
- OTHER
-
laboratory biomarker analysis
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
SWOG Cancer Research Network
lead NETWORK
Principal Investigators
-
Lisa Rimsza, MD · University of Arizona
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-12-31
- Primary Completion
- 2012-06-30
- Completion
- 2012-06-30
More Related Trials
-
DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701
NCT01057459 ·Status: COMPLETED
-
S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
NCT00770224 ·Status: COMPLETED ·Phase: PHASE2
-
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
NCT00896519 ·Status: UNKNOWN ·Phase: PHASE2
-
Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma
NCT00227695 ·Status: COMPLETED ·Phase: PHASE3
-
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
NCT01856192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma
NCT00005631 ·Status: COMPLETED ·Phase: PHASE2
-
Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden
NCT00136552 ·Status: COMPLETED ·Phase: PHASE3
-
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
NCT00670358 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
NCT01476787 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
NCT05888493 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients
NCT01303887 ·Status: COMPLETED ·Phase: PHASE3
-
Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma
NCT05189782 ·Status: UNKNOWN
-
Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma
NCT01829568 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)
NCT02303119 ·Status: COMPLETED ·Phase: PHASE3
-
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma
NCT01539174 ·Status: WITHDRAWN ·Phase: PHASE2
-
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
NCT06553352 ·Status: RECRUITING ·Phase: PHASE2
-
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
NCT05565417 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
NCT00335140 ·Status: TERMINATED ·Phase: PHASE2
-
Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
NCT00112931 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
NCT05100862 ·Status: RECRUITING ·Phase: PHASE3
-
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
NCT00060346 ·Status: TERMINATED ·Phase: PHASE2
-
Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance
NCT06070961 ·Status: RECRUITING
-
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia
NCT00133991 ·Status: COMPLETED ·Phase: PHASE2
-
A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma
NCT00930514 ·Status: COMPLETED ·Phase: PHASE1
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
NCT06510361 ·Status: RECRUITING ·Phase: PHASE2